HOYA Surgical Optics announces new publication for Vivinex Impress™, and enhanced monofocal IOL
The journal article, titled "Comparison of Visual Acuity Outcomes of Enhanced Monofocal Versus Standard Monofocal Intraocular Lenses from a Randomized, Multicenter, Active-Controlled Trial," was published in the April 2025 issue of the Journal of Refractive Surgery. This peer-reviewed publication describes the randomized, active-controlled clinical trial comparing the visual performance of the Vivinex Impress™ enhanced monofocal intraocular lens (IOL) against a well-established conventional monofocal IOL.
This is the first publication from the trial and is focused on visual acuity, defocus curves, and independence of intermediate gain from pupil size and axial length. A second publication is under development with a focus on other end results.
The key findings from the study include1:
- Statistically significant improvements were observed in monocular distance-corrected intermediate visual acuity (DCIVA) and uncorrected intermediate visual acuity with the enhanced monofocal IOL
- Enhanced monocular visual acuity was recorded in photopic defocus curves ranging from -1.00 to -2.50 D
- The intermediate vision benefits of the enhanced monofocal IOL were found to be independent of pupil size and axial length
- Adverse events for the enhanced monofocal IOL were within ISO Safety and Performance Endpoint rates
For comprehensive insights and detailed data, please refer to the full article: https://journals.healio.com/eprint/GXMFXSK3KQHKJFAFNQKT/full
Bob Anello, Chief Clinical, Regulatory and Medical Affairs Officer, HOYA Surgical Optics, said:
“We are delighted to share our latest peer-reviewed journal article, presenting the positive clinical trial results for Vivinex Impress™. This achievement underscores our commitment and dedication to delivering advanced intraocular lens technologies that will enable ophthalmic surgeons to restore sight and improve the quality of life for millions of cataract patients.”
References
1. https://journals.healio.com/eprint/GXMFXSK3KQHKJFAFNQKT/full
About HOYA Surgical Optics
Cataract continues to be a major cause of blindness worldwide, with cataract surgery being one of the most commonly performed eye surgeries in the world. The number of cataract surgeries performed throughout the world is expected to increase to almost 33.4 million by 2024.
HOYA Surgical Optics develops technologies that enable surgeons to improve vision and quality of life for millions of people suffering from cataract – to help them celebrate life, visually. These products have been known to offer safety, reliability and ease of use. Quality, Trust, Dedication and Attention to detail are deeply rooted in the Japanese heritage of the HOYA brand. For more information, please visit https://www.hoyasurgicaloptics.com.
HOYA Surgical Optics is a division of HOYA Corporation, a global technology company based in Japan. HOYA leverages over 80 years of excellence in optics design and innovation.
